OB-cadherin Activators
OB-cadherin, formally known as osteoblast cadherin, plays a crucial role in the biological processes of cell adhesion, particularly among osteoblasts, which are pivotal in bone formation and skeletal architecture. This protein is a member of the cadherin superfamily, characterized by their calcium-dependent adhesion properties, which facilitate tight binding between cells, enabling tissue structuring and integrity. OB-cadherin's specific function in osteoblasts underscores its importance in bone development, where it mediates cell-cell interactions that are essential for the differentiation and maintenance of osteoblasts, and by extension, the regulation of bone density and health. The expression and activity of OB-cadherin are meticulously regulated within the cellular environment, highlighting its significance in the orchestration of cellular processes that govern bone formation and remodeling. The precise interactions mediated by OB-cadherin contribute to the establishment of a robust extracellular matrix, which is critical for bone strength and resilience.
The activation of OB-cadherin is a complex process that involves several biochemical and cellular mechanisms, ensuring the precise control of its adhesive functions and its role in signal transduction. Activation is typically mediated by the interaction with calcium ions, which prompts a conformational change in the cadherin molecule, enhancing its adhesive capabilities. This calcium-dependent mechanism is fundamental to the functionality of cadherins, including OB-cadherin, enabling the dynamic regulation of cell adhesion in response to the changing physiological requirements of bone tissue. Moreover, the intracellular domain of OB-cadherin interacts with various proteins, including catenins, which link cadherins to the actin cytoskeleton, thereby stabilizing cell-cell adhesion and transducing signals that regulate gene expression and cellular responses. The phosphorylation of OB-cadherin or its associated proteins is another critical regulatory mechanism, modulating the strength of cell adhesion and the downstream signaling pathways that influence osteoblast function and bone formation.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin directly stimulates adenylyl cyclase, leading to increased cAMP levels, a secondary messenger that activates protein kinase A (PKA). PKA activation enhances the phosphorylation and activation of OB-cadherin, promoting its function in cell-cell adhesion. | ||||||
8-Bromoadenosine 3′,5′-cyclic monophosphate | 23583-48-4 | sc-217493B sc-217493 sc-217493A sc-217493C sc-217493D | 25 mg 50 mg 100 mg 250 mg 500 mg | $108.00 $169.00 $295.00 $561.00 $835.00 | 2 | |
8-Bromo-cAMP serves as a cell-permeable cAMP analog, bypassing adenylyl cyclase activation. It activates PKA, which then phosphorylates targets including OB-cadherin, facilitating its activation and strengthening cell-cell adhesion mechanisms. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX, a non-selective phosphodiesterase inhibitor, prevents cAMP degradation, sustaining its intracellular levels. Elevated cAMP activates PKA, which in turn activates OB-cadherin by phosphorylation, enhancing cell adhesion properties. | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $41.00 $104.00 $201.00 $1774.00 $16500.00 | ||
Epinephrine binds to adrenergic receptors, leading to adenylyl cyclase activation and cAMP production. Increased cAMP activates PKA, which phosphorylates and activates OB-cadherin, promoting its cell adhesion function. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram, by inhibiting PDE4, increases intracellular cAMP levels. This elevation activates PKA, subsequently phosphorylating and activating OB-cadherin, thus enhancing its cell adhesion capabilities. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Isoproterenol, a beta-adrenergic agonist, increases adenylyl cyclase activity, raising cAMP levels. The activation of PKA, which follows, leads to the phosphorylation and activation of OB-cadherin, promoting cell adhesion. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $47.00 $136.00 $492.00 $4552.00 | 74 | |
Dibutyryl-cAMP, a stable cAMP analog, directly activates PKA without the need for adenylyl cyclase. Activated PKA phosphorylates OB-cadherin, enhancing its function in cell-cell adhesion. | ||||||
Milrinone | 78415-72-2 | sc-201193 sc-201193A | 10 mg 50 mg | $165.00 $697.00 | 7 | |
Milrinone, a selective PDE3 inhibitor, increases cAMP levels in cardiac cells, indirectly leading to PKA activation. PKA then activates OB-cadherin by phosphorylation, improving cell adhesion. | ||||||
Cilostamide (OPC 3689) | 68550-75-4 | sc-201180 sc-201180A | 5 mg 25 mg | $92.00 $357.00 | 16 | |
Cilostamide, another selective PDE3 inhibitor, elevates cAMP by inhibiting its breakdown. This leads to PKA activation, which phosphorylates OB-cadherin, thereby activating it and promoting cell-cell adhesion. | ||||||
Anagrelide hydrochloride | 58579-51-4 | sc-203513 sc-203513A | 10 mg 50 mg | $103.00 $587.00 | 1 | |
Anagrelide hydrochloride, through its inhibition of PDE3, increases cAMP levels. The subsequent activation of PKA results in the phosphorylation and activation of OB-cadherin, enhancing adhesion between cells. | ||||||